A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...

Cretostimogene monotherapy achieves a 75.5% complete response rate in high-risk, BCG-unresponsive non-muscle invasive bladder cancer patients. The treatment maintains a 46% complete response at 12 ...

A new systematic review explores how prehabilitation—through exercise, education, nutrition, and lifestyle changes—affects ...

Up to 40% of patients with non-muscle-invasive bladder cancer do not respond to traditional immunotherapy for the condition, known as BCG treatment, which uses a weakened bacteria. In April 2024 ...

But when cancer develops, it often uses tactics to fool the immune ... In this trial, the RUTI vaccine was administered alongside the standard BCG treatment. The results were promising: RUTI ...

Johnson & Johnson’s Balversa was found to extend the lives of urothelial cancer patients with a genetic alteration ...

Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase ...